Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Phase 2 Unknown 100 enrolled Sun Yat-sen University

NaSingle-groupOpen-labelTreatment

Summary

This prospective study was conducted to evaluate the efficacy and safety profiles of Modified MRCUKALLⅫ/ECOGE2993 Regimen in young adults with newly diagnosed, low-risk, Philadelphia chromosome negative acute lymphoblastic leukaemia.

Timeline

Start: 2016-01
Primary completion: 2019-01
Completion: 2019-01

Publications

Results Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, Lazarus HM, Franklin IM, Litzow MR, Ciobanu N, Prentice HG, Durrant J, Tallman MS, Goldstone AH; ECOG; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005 Dec 1;106(12):3760-7. doi: 10.1182/blood-2005-04-1623. Epub 2005 Aug 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Cyclophosphamide	Other / unclassified	650 mg/m2	Intravenous
Background	Cytarabine	Small molecule	75 mg/m2	Intravenous
Background	Daunorubicin	Small molecule	25 mg/m2	Intravenous
Background	Daunorubicin	Small molecule	60 mg/m2	Intravenous
Background	Dexamethasone	Small molecule	10 mg/m2	Oral
Background	Etoposide	Small molecule	100 mg/m2	Intravenous
Background	MERCAPTOPURINE ANHYDROUS	Small molecule	60 mg/m2	Oral
Background	MERCAPTOPURINE ANHYDROUS	Small molecule	75 mg/m2	Oral
Background	Methotrexate	Small molecule	12.5 mg	Intrathecal
Background	Methotrexate	Small molecule	20 mg/m2	Intravenous
Background	Methotrexate	Small molecule	3 g	Intravenous
Background	Pegaspargase	Protein / enzyme biologic	2500 unknown	Intramuscular
Background	Prednisone	Other / unclassified	60 mg/m2	Oral
Background	Thioguanine	Small molecule	60 mg/m2	Oral
Background	Vincristine	Small molecule	1.4 mg/m2	Intravenous
Background	intrathecal cytarabine	Unknown	50 mg	Intrathecal

Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL

Summary

Timeline

Publications

Drugs

Indications